AstraZeneca Q2 EPS $1.07 Beats $0.95 Estimate, Sales $11.42B Beat $10.96B Estimate
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca reported Q2 earnings of $1.07 per share, beating the analyst consensus estimate of $0.95 by 13.16%. This is a 25% increase from the same period last year. The company also reported quarterly sales of $11.42 billion, beating the analyst consensus estimate of $10.96 billion by 4.20%. This is a 6.03% increase from the same period last year.
July 28, 2023 | 7:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Q2 earnings and sales exceeded analyst estimates, indicating a strong financial performance. This could potentially lead to a positive impact on the company's stock price in the short term.
AstraZeneca's Q2 earnings and sales have exceeded analyst estimates, which is generally seen as a positive sign of the company's financial health and performance. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100